Literature DB >> 18245146

Case-control study of acute renal failure in patients with cystic fibrosis in the UK.

A Smyth1, S Lewis, C Bertenshaw, I Choonara, J McGaw, A Watson.   

Abstract

BACKGROUND: There has been a recent increase in the number of reported cases of acute renal failure (ARF) in cystic fibrosis (CF). A case-control study was conducted to determine the factors which are associated with an increased risk of ARF.
METHODS: 24 cases of confirmed ARF were identified in patients with CF from 20 UK CF centres presenting between 1997 and 2004. Using the UK CF database, sex- and age-matched controls were identified. Risk factors were analysed by conditional logistic regression and Mantel-Haenszel analysis.
RESULTS: 21 of the 24 patients with ARF had received an aminoglycoside at the time of their episode of ARF or in the preceding week compared with only 3 of 42 controls during the same time period (OR 81.8, 95% CI 4.7 to 1427, p<0.001). In the year before the episode of ARF, significantly more cases than controls had received gentamicin (19/24 cases vs 1/42 controls, p<0.001). The numbers receiving tobramycin were similar (9/24 cases vs 16/42 controls, p = 0.9). A known risk factor for renal impairment (prior renal disease, acute dehydration or long-term treatment with a nephrotoxic drug) was present in 18/24 cases and 7/42 controls (OR 24.0, 95% CI 3.1 to 186.6, p = 0.002).
CONCLUSIONS: In patients with CF the use of an intravenous aminoglycoside is a risk factor for ARF; gentamicin is more nephrotoxic than tobramycin. Most patients who develop ARF have a risk factor which necessitates withholding aminoglycosides or more closely monitoring their use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245146     DOI: 10.1136/thx.2007.088757

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  23 in total

1.  Minimizing the toxicity of aminoglycosides in cystic fibrosis.

Authors:  Alan R Smyth
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

2.  Serum cystatin C for acute kidney injury evaluation in children treated with aminoglycosides.

Authors:  Lorraine Lau; Zubaida Al-Ismaili; Maya Harel-Sterling; Michael Pizzi; Jillian S Caldwell; Melissa Piccioni; Larry C Lands; Theresa Mottes; Prasad Devarajan; Stuart L Goldstein; Michael R Bennett; Michael Zappitelli
Journal:  Pediatr Nephrol       Date:  2016-10-14       Impact factor: 3.714

3.  Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.

Authors:  Jayesh Bhatt; Nikki Jahnke; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2019-09-04

4.  Daily serum creatinine monitoring promotes earlier detection of acute kidney injury in children and adolescents with cystic fibrosis.

Authors:  Kevin J Downes; Marepalli B Rao; Laurie Kahill; Hovi Nguyen; John P Clancy; Stuart L Goldstein
Journal:  J Cyst Fibros       Date:  2014-04-06       Impact factor: 5.482

5.  Safety of Extended Interval Tobramycin in Cystic Fibrosis Patients Less an 6 Years Old.

Authors:  Alexandria Arends; Rebecca Pettit
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

6.  Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis.

Authors:  Kevin J Downes; Neha R Patil; Marepalli B Rao; Rajesh Koralkar; William T Harris; John P Clancy; Stuart L Goldstein; David J Askenazi
Journal:  Pediatr Nephrol       Date:  2015-04-26       Impact factor: 3.714

7.  Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.

Authors:  Stefanie Hennig; Joseph F Standing; Christine E Staatz; Alison H Thomson
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

Review 8.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

Review 9.  Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.

Authors:  Andrew Prayle; Alan Watson; Heather Fortnum; Alan Smyth
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

Review 10.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.